Sleep diagnostics company Itamar Medical acquired by ZOLL Medical for $538 million
The deal for the Israeli company that develops solutions to aid in the diagnosis of respiratory sleep disorders represents a premium of 50.2% over the price of its shares on Nasdaq
Israeli medical device and digital health company Itamar Medical announced on Monday that it has been acquired by ZOLL Medical Corporation for approximately $538 million. Itamar is focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. ZOLL is an Asahi Kasei company that manufactures medical devices and related software solutions.
Itamar Medical, which was traded on Nasdaq and the Tel Aviv Stock Exchange, pioneered the WatchPAT Home Sleep Apnea Device, an innovative sleep apnea diagnosis program for patients and healthcare professionals. The WatchPAT device is FDA-cleared and continues to gain recognition as a safe and effective method for home-based testing for sleep apnea.
Itamar Medical co-founder and chairman Giora Yaron. Photo: Orel Cohen
ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for $31 per American Depository Share (ADS), or $1.03 (equivalent to approximately NIS 3.31) per ordinary share, in cash. The offer of $31 per ADS in cash represents a premium of 50.2% over the price of Itamar Medical’s ADS on Nasdaq this past Friday.
“The integration of Itamar’s WatchPAT technology and Digital Health solution for sleep apnea with ZOLL Medical's commercial footprint will accelerate our mission of advancing home sleep medicine to benefit the population of undiagnosed and untreated patients,” said Gilad Glick, President and Chief Executive Officer of Itamar Medical.
- Israeli medtech company CartiHeal to be acquired for $500 million by Bioventus
- Antidote Health raises $12 million seed round to set up virtual HMO in the U.S.
- Israeli medical device company Memic to merge with SPAC at more than $1 billion valuation
ZOLL Medical is expecting the transaction to close by the end of 2021, assuming typical regulatory and shareholder approval timeframes. Once the acquisition is completed, it is expected that Itamar Medical’s principal operations will continue at its current location in Caesarea, Israel, including its R&D and Digital Health Technology centers, as well as the production center.
“ZOLL Medical is committed to improving outcomes for underserved patients suffering from serious cardiopulmonary conditions,” said Jon Rennert, CEO of ZOLL Medical. “It is currently estimated that 60% of cardiovascular patients suffer from some form of sleep apnea, and the majority of these patients go undiagnosed. The combination of ZOLL Medical and Itamar Medical will help more patients receive diagnosis and treatment for sleep-disordered breathing. We look forward to helping strengthen the collaboration between the worlds of cardiology and sleep medicine.”
Itamar Medical WatchPAT. Photo: Itamar Medical